EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors

Blood

Volumn 116, Issue 26, 2010, Pages 6014-6017

  Daghistani, Mustafa ^a   Marin, David ^a   Khorashad, Jamshid Sorouri ^a   Wang, Lihui ^b   May, Philippa C ^a   Paliompeis, Christos ^a   Milojkovic, Dragana ^a   De Melo, Valeria A ^a   Gerrard, Gareth ^a   Goldman, John M ^a   Apperley, Jane F ^a   Clark, Richard E ^b   Foroni, Letizia ^a   Reid, Alistair G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE EVI 1; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 78650676294     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-264234     Document Type: Article

References (10)

1. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109(6):2303-2309. (Pubitemid 46425867)
2. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540- 3546.
3. Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. Haematologica. 2010;95(2):224-231.
4. Vinatzer U, Mannhalter C, Mitterbauer M, et al. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer. 2003;36(1):80-89.
5. Groschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28(12):2101-2107.
6. Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood. 2008;111(8):4329-4337.
7. Cattaneo F, Nucifora G. EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression. J Cell Biochem. 2008;105(2):344-352.
8. Ogawa S, Mitani K, Kurokawa M, et al. Abnormal expression of Evi-1 gene in human leukemias. Hum Cell. 1996;9(4):323-332.
9. Ogawa S, Kurokawa M, Tanaka T, et al. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia. 1996;10(5):788-794.
10. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358- 3363.